Loading
A phase 3 trial of Busulfan and Treosulfan in Acute myeloid leukaemia, run by medac GmbH, completed.
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) is a phase 3 interventional study registered as NCT00822393 by medac GmbH, with 570 participants recorded, started 2008-11-24 and reaching its primary completion in 2018-01-25. Interventions recorded: Busulfan, Treosulfan. Conditions recorded: Acute Myeloid Leukemia, Myelodysplastic Syndrome.
Linked to the drug Treosulfan because the registry names it among its interventions and Acute myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.
Shares Busulfan, Acute myeloid leukaemia and the tag pipeline.
Shares Treosulfan and the tag pipeline.
Shares Busulfan and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.